VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC

May 29, 2026 - 00:56

Swiss biotech firm VERAXA Biotech AG has secured a significant financial commitment as it prepares to list on the Nasdaq. The company announced it has entered into a securities purchase agreement with an institutional investor for $27.5 million. This new funding is separate from an existing $50 million share purchase agreement the company already holds with Lincoln Park Capital Fund.

Alongside the financing, VERAXA has applied to list its shares on the Nasdaq under the ticker symbol "VRXA." The company plans to achieve this listing through a business combination with Voyager Acquisition Corp., a special purpose acquisition company. The move is expected to provide VERAXA with the capital and public market access needed to advance its pipeline of therapies.

The company is focused on developing treatments for diseases with high unmet medical needs. The combined funding from the institutional investor and the Lincoln Park agreement is intended to support clinical development and operational growth. The deal with Voyager is subject to customary closing conditions and approvals.